346 related articles for article (PubMed ID: 21519925)
21. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A; Gold R
Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
[TBL] [Abstract][Full Text] [Related]
22. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
23. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
24. Fingolimod phosphate promotes the neuroprotective effects of microglia.
Noda H; Takeuchi H; Mizuno T; Suzumura A
J Neuroimmunol; 2013 Mar; 256(1-2):13-8. PubMed ID: 23290828
[TBL] [Abstract][Full Text] [Related]
25. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
26. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
27. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.
Egom EE; Ke Y; Musa H; Mohamed TM; Wang T; Cartwright E; Solaro RJ; Lei M
J Mol Cell Cardiol; 2010 Feb; 48(2):406-14. PubMed ID: 19852968
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
[TBL] [Abstract][Full Text] [Related]
29. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
30. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
31. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
Payne SG; Oskeritzian CA; Griffiths R; Subramanian P; Barbour SE; Chalfant CE; Milstien S; Spiegel S
Blood; 2007 Feb; 109(3):1077-85. PubMed ID: 17008548
[TBL] [Abstract][Full Text] [Related]
32. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Don AS; Martinez-Lamenca C; Webb WR; Proia RL; Roberts E; Rosen H
J Biol Chem; 2007 May; 282(21):15833-42. PubMed ID: 17400555
[TBL] [Abstract][Full Text] [Related]
33. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
34. FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes.
Wang M; Lu L; Liu Y; Gu G; Tao R
Exp Mol Pathol; 2014 Oct; 97(2):218-24. PubMed ID: 25034934
[TBL] [Abstract][Full Text] [Related]
35. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Zehra Okus F; Busra Azizoglu Z; Canatan H; Eken A
Int Immunopharmacol; 2022 Jun; 107():108665. PubMed ID: 35255303
[TBL] [Abstract][Full Text] [Related]
36. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.
Bajwa A; Rosin DL; Chroscicki P; Lee S; Dondeti K; Ye H; Kinsey GR; Stevens BK; Jobin K; Kenwood BM; Hoehn KL; Lynch KR; Okusa MD
J Am Soc Nephrol; 2015 Apr; 26(4):908-25. PubMed ID: 25145931
[TBL] [Abstract][Full Text] [Related]
37. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Tian YL; Jin J; Wang XJ
Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
[TBL] [Abstract][Full Text] [Related]
38. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
Takabe K; Paugh SW; Milstien S; Spiegel S
Pharmacol Rev; 2008 Jun; 60(2):181-95. PubMed ID: 18552276
[TBL] [Abstract][Full Text] [Related]
39. FTY720 for cancer therapy (Review).
Zhang L; Wang HD; Ji XJ; Cong ZX; Zhu JH; Zhou Y
Oncol Rep; 2013 Dec; 30(6):2571-8. PubMed ID: 24100923
[TBL] [Abstract][Full Text] [Related]
40. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
